A Phase I Study of ABT-199 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma

Protocol
11-152
Full Title
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Phase
I
Disease Status
Relapsed/Refractory
Purpose

The purpose of this study is to find the highest dose of the investigational drug ABT-199 that can be given to patients with chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), or non-Hodgkin lymphoma (NHL) that has persisted or returned despite prior therapy. ABT-199 works by blocking Bcl-2, a protein overproduced by many CLL, SLL, and NHL cells that makes these cancer cells live longer.

ABT-199 is a tablet that is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have CLL, SLL, or NHL that has persisted or returned despite prior therapy.
  • Patients should have recovered from the side effects of prior therapies before entering the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • Patients must be age 18 or older.

For more information and to inquire about eligibility for this study, please contact Dr. John Gerecitano at 212-639-3748.

Disease(s)
Leukemia: Chronic Lymphocytic Leukemia
Lymphoma
Lymphoma: Non-Hodgkin's Lymphoma
Locations